SQ Innovation today announced that results of the SUBCUT HF II trial of its product Lasix® ONYU, will be presented at Heart Failure 2026, the annual congress of the Heart Failure Association (HFA) of ...
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET) The median time post-HCT was ...
Total hip arthroplasty leads to the best outcomes in the treatment of moderate-to-severe hip osteoarthritis, according to a ...
The growing body of clinical evidence for RevitalVision supports the integration of perceptual learning into routine ...
Tesamorelin can selectively reduce visceral fat, as demonstrated in RCTs. But the real story is what it reveals about ...
A postbiotic reduced allergic rhinitis symptoms in a clinical trial. Could microbiome therapies transform treatment? Read ...
Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...
We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving adults with acute, nonarteritic central retinal artery occlusion who had symptom onset within 4.5 hours ...
Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and bladder control in older adults. The disorder is treated with shunt surgery, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results